NIMG-07. INFLUENCE OF 2 CONTRASTING TREATMENT PLANNING APPROACHES ON TUMOR TREATING FIELDS (TTFIELDS) INTENSITY IN THE GROSS TUMOR VOLUME (GTV) AND PERITUMORAL BRAIN ZONE (PBZ) IN GLIOBLASTOMA
نویسندگان
چکیده
منابع مشابه
Analysis of physical characteristics of Tumor Treating Fields for human glioblastoma
Tumor Treating Fields (TTFields) therapy is an approved treatment that has known clinical efficacy against recurrent and newly diagnosed glioblastoma. However, the distribution of the electric fields and the corresponding pattern of energy deposition in the brain are poorly understood. To evaluate the physical parameters that may influence TTFields, postacquisition MP-RAGE, T1 and T2 MRI sequen...
متن کاملTumor treating fields: a new standard treatment for glioblastoma?
PURPOSE OF REVIEW Tumor treating fields (TTFields), an external therapeutic device with antimitotic properties, is a Food and Drug Administration approved treatment for recurrent glioblastoma (GBM) that has been reported to be efficacious in newly diagnosed GBM as well. RECENT FINDINGS Preclinical data show that TTFields is an antimitotic agent that additionally augments response to alkylator...
متن کاملTumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells
BACKGROUND Tumor Treating Fields (TTFields) are an anti-neoplastic treatment modality delivered via application of alternating electric fields using insulated transducer arrays placed directly on the skin in the region surrounding the tumor. A Phase 3 clinical trial has demonstrated the effectiveness of continuous TTFields application in patients with glioblastoma during maintenance treatment w...
متن کاملThe Evolving Role of Tumor Treating Fields in Managing Glioblastoma
Glioblastoma (GBM) is a devastating brain tumor with poor prognosis despite advances in surgery, radiation, and chemotherapy. Survival of patients with glioblastoma remains poor, with only 1 in 4 patients alive at 2 years, and a 5-year survival rate of about 5%. Recurrence is nearly universal and, after recurrence, prognosis is poor with very short progression-free survival and overall survival...
متن کاملRationale and Background on Tumor-Treating Fields for Glioblastoma.
BACKGROUND More than 150 years after the first description of glioma cells, patients with glioblastoma (GBM) continue to have a poor prognosis despite standard-of-care therapy. With the introduction of tumor-treating fields (TTFields) therapy for the treatment of recurrent GBM in 2011 and for newly diagnosed GBM in 2015, the opportunity to increase progression-free survival and overall survival...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-Oncology
سال: 2016
ISSN: 1522-8517,1523-5866
DOI: 10.1093/neuonc/now212.519